Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00545519 · ClinicalTrials.gov registry record · Phase 1

A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma

A Phase 1 study of Relapsed or Refractory Multiple Myeloma, sponsored by Washington University School of Medicine.

Completed
Registry status
Phase 1
Development phase
6
Enrollment target
1
Study location

NCT00545519: Completed Phase 1 study of Relapsed or Refractory Multiple Myeloma, sponsored by Washington University School of Medicine.

NCT00545519 is a Phase 1 study of Relapsed or Refractory Multiple Myeloma that has completed, run by Washington University School of Medicine. The registered enrollment target is 6 participants, below the 342-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00545519, a Phase 1 study of Relapsed or Refractory Multiple Myeloma, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
Phase 1
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

To determine the maximum tolerated dose and dose limiting toxicity of thymoglobulin in multiple myeloma patients. To determine the overall response rate (CR+PR) of patients with relapsed or refractory multiple myeloma treated with Thymoglobulin. To determine the time to response, duration of response, and time to progression and overall survival of patients treated with Thymoglobulin. To determine the safety and tolerability of Thymoglobulin in these patients. To assess the changes in lymphocyte apoptosis and apoptotic signaling in treated patients.

Conditions Studied

Relapsed or Refractory Multiple Myeloma

Interventions

  • DRUG thymoglobulin

Study Locations (1)

Missouri

  • Washington Unvierstiy in St. Louis - St Louis

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2006-10
Est. Completion 2008-03
Phase Phase 1
Washington University School of Medicine

1,502 total trials

What the finished NCT00545519 record still lists

NCT00545519 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 342-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Relapsed or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which thymoglobulin is the first listed.

NCT00545519 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT00545519 about?

NCT00545519 is a clinical study titled "A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma". To determine the maximum tolerated dose and dose limiting toxicity of thymoglobulin in multiple myeloma patients. To determine the overall response rate (CR+PR) of patients with relapsed or refractory multiple myeloma treated with Thymoglobulin. To determine the time to response, duration of respo...

What is the current status of trial NCT00545519?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2006-10. Estimated completion is 2008-03.

What conditions does trial NCT00545519 study?

This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma.

What interventions are being tested in trial NCT00545519?

The interventions under investigation include: thymoglobulin (DRUG).

Who is sponsoring clinical trial NCT00545519?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00545519 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsed or Refractory Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00545519's enrollment target sits among peer trials

6 11th of 10 the lowest of 10 other Relapsed or Refractory Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Relapsed or Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00545519, the US trial registry maintained by the National Library of Medicine. NCT00545519 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.